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Incessant malaria endemicity in the tropics and subtropical regions and the recent work done on the 
synthesis of metal drug complexes of antimalarial drugs and the evaluation of their antimalarial 
activities in vitro, has led to the development of this study. Quinine-Zinc complex (QZ) was synthesized 
using a modification of Singla and Wadhwa method. Melting point determination, TLC analysis, infra 
red, ultra violet, atomic absorption spectroscopy and mole ratio determination were all carried out on 
the complex synthesized. Direct measurement of the antimalarial activity of the potential new drug (QZ) 
against parasite growth in vitro was used to comparatively ascertain the antimalarial activity of QZ 
relative to Quinine sulphate (QS). Measurement of antimalarial activity was carried out based on the 
inhibition of parasite growth with respect to inhibition of schizont formation in freshly collected infected 
blood samples from patients. The results showed that QZ complex was formed and its antimalarial 
activity was three times that of QS alone. This study suggests that the quinine-zinc complex could have 
a better therapeutic activity than quinine.  
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INTRODUCTION 
 
Today, about 300 – 500 million malaria cases each year 
cause 1.5 – 2.7 million deaths. By this analysis, malaria 
accounts for more than 90% of deaths in children below 5 
years of age in Africa (Good, 2001; Sachs and Malaney, 
2002). The challenge of malaria especially to sub Saha-
ran African nations continues to widen without easily 
defined limits as drug resistance to most antimalarial 
drugs, insecticide resistance in mosquitoes, and other cli-
matic and social-cultural factors complicate malaria re-
search (Krettli et al., 2001). The development of resis-
tance to antimalarial drugs by malaria parasites is the 
most disturbing factor. Today, malaria parasite has been 
confirmed to show notable resistance to inexpensive 
drugs like chloroquine, quinine, sulphadoxine/ pyrimetha-
mine and a number of other drugs in this category. Newer 
drugs   however   cost   7 - 60 times   as  much  as  these 
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(Olliaro et al., 1996). The challenge of drug resistance is 
leading malaria researchers in the direction of antimala-
rial medicinal plant research. Since many drugs e.g. 
quinine and artemisinin were isolated from plants, investi-
gation of compounds within traditional plants is beginning 
to get attention (Phillipson, 1991). However, a number of 
these compounds within traditional plants may not have 
been thoroughly studied for toxicity and interaction with 
other xenobiotics. 
Zinc in the therapeutic dosage form is not known to 
cause any immediate side effects other than occasional 
stomach upset usually when taken on an empty stomach 
(Sandstead, 1995). Instead, long term usage of zinc 
supplement has been shown to reduce the chances of 
getting sick (Marshall, 1998). Zinc supplement during 
pregnancy has been found to improve the birth weight 
and head size of new born (Goldenberg et al., 1995). 
Evidence has also shown that when zinc is taken at fairly 
high doses (100–10 mg/day), it will reduce the symptoms 
of acne to an extent comparable to that of tetracycline 
(Cunliffe et al., 1979), prevent the development  of  sickle 
  
 
 
cell crisis in sickle cell anemia patients (Gupta and Chan-
bey, 1995) and speed up the healing of stomach ulcers 
(Frommer, 1975). 
Due to the anti-ulcer and anti-inflammatory properties 
of zinc, aspirin-zinc complex has been synthesized in 
ratio 2:1 of aspirin and zinc respectively (Singla and 
Wadhwa, 1994). This has been shown to increase the 
anti-inflammatory effect of aspirin, enhance the gastro-
intestinal absorption of aspirin and present aspirin in a 
better tolerated dosage form (Singla and Wadhwa, 1994).  
This work is designed with the intention of investigating 
the possible antiplasmodial activity of a complex of two 
well-studied, readily available compounds, Quinine and 
Zinc, as a viable and affordable antimalarial option. 
 
 
MATERIALS AND METHODS 
 
This research was carried out in three stages namely: 
 
• Extraction and analysis of Quinine sulphate (QS) 
• Synthesis and analysis of Quinine-zinc complex (QZ) 
• Comparative determination of antiplasmodial activity of Quinine 
sulphate and Quinine-zinc complex 
 
The first two stages were carried out in the laboratory of the 
Pharmaceutical Chemistry department, University of Ibadan, Oyo 
state, Nigeria, while the third stage of this work was carried out at 
the Institute of Medical Research and Technology (IMRAT), College 
of Medicine, University of Ibadan, Oyo state, Nigeria. 
 
 
Extraction of Quinine sulphate 
 
Quinine sulphate was extracted from its tablet form (Quinine sul-
phate, Cox Pharmaceuticals, AH Cox and Co Ltd., England) 
according to the method specified in British Pharmacopoeia (British 
Pharmacopoeia, 1998). Identity and purity assessment tests were 
carried out using melting point determination and thin layer chroma-
tography (TLC) for both the extracted QS and the standard Quinine 
sulphate powder (BDH Chemicals, Poole, UK).  
 
 
Synthesis and analysis of QZ  
 
A modification of Singla and Wadhwa method was employed 
(Singla and Wadhwa, 1994). QZ was formed in 60% v/v aqueous 
ethanolic extract. 7.83 g Quinine sulphate (0.1 moles) was added to 
700 ml ethanol. The solution was stirred until dissolution was 
complete. The solution was then added slowly with constant stirring 
to a solution of ZnSO4.7H2O (1.4375 g, 0.005 moles) in 467 ml wa-
ter. Turbidity appeared which (between 10 – 15oC) led to formation 
of white crystals. The crystals were filtered, washed with minimum 
quantity of cold distilled water, dried under vacuum to constant 
weight to give QZ. 
Infra red spectra of both QS and QZ in the range of 600 – 4000 
cm-1 were taken with BUCK M500 spectrometer (Buck Scientific, 
East Norwalk) in nujol. 0.01 g QZ and QS were dissolved sepa-
rately in 5 ml (0.01 M) HCl. Ultra violet spectroscopy was also 
carried out on the two compounds using PERKINS ELMER 3b pp 
uv/ visible spectrophotometer (Perkin Elmer Life and Analytical 
Sciences Inc., USA)  with  recorder.  Zinc content was determined 
with   atomic   absorption   spectroscopy   using   AANALYST   200 
(PerkinElmer Life and Analytical Sciences Inc., USA). Atomic 
absorption spectrometry was used in the determination of mole 
ratio of Quinine and Zinc in QZ. 
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Comparative determination of antiplasmodial activity of QS 
and QZ in vitro 
 
WHO (1990) standard micro in vitro susceptibility (MARK II) tech-
nique was used to determine the in vitro sensitivity of P. falciparum 
to the QZ and QS drugs. The test kits were obtained from IMRAT. 
0.0134 g of QS was dissolved in 100 ml distilled water (stock 
solution 1). 1 ml of stock solution 1 was drawn with pipette into 10 
ml falcon tube and made up to 10 ml with complete medium (stock 
solution 2). Series of dilution of stock solution 2 were used to obtain 
150 µl of samples containing 4, 8, 16, 32, 64, 128, 160, 256, 320, 
620, 1280, 2560  pmols of QS and used to medicate wells in the 
columns labeled 3 and 9 of B - H. 0.0128 g of QZ was dissolved in 
100 ml water and similar procedure as that used for the preparation 
of different dilutions of QS was followed to obtain same concen-
trations of QZ as that of QS in pmols and used to medicate wells in 
columns labeled 5 and 11 of the micro plate. 150 µl of complete 
culture medium was used to medicate wells in row labeled A in the 
columns as control. The experiment was carried out in duplicates. 
 
 
Cultivation procedure 
 
The methods of Trager and Jenson, (1976) and Jenson and Trager, 
(1977) were employed for cultivation of Plasmodium culture. 
Positive blood sample collected from malaria patients in bijou bottle 
containing ACD (acid citrate dextrose) was suspended and washed 
three times with incomplete RPMI (Rosewell Park Memorial 
Institute) 1640 medium (Gibco BRL, Scotland) by centrifugation at 
1500 g for 5 min at room temperature. The supernatant and buffy 
coats were carefully removed aseptically under the lamina flow 
hood at the end of each wash. In 35 mm sterile plastic Petri dishes, 
0.5 ml of the washed packed parasitized red blood cells and 4.5ml 
of complete medium were mixed gently to start the culture. All the 
wells with appropriate dilutions of sample drugs in them were dosed 
with 50 µL of the blood/medium mixture in ratio 1:9 respectively 
using the 50 µL Eppendorf pipette and disposable sterile tips. The 
blood/medium mixture was gently shaken from time to time to 
ensure that the blood was kept in suspension. The microlitre plates 
were covered and labeled appropriately and placed in a glass 
incubator into which a lit candle was put. The desiccator’s lid was 
removed. The culture plates were maintained at 37°C in a water-
jacketed incubator for a period of 24 - 30 h. 
 
 
Pre-harvest analysis of cultures 
 
Smear made 24 h after the start of the culture was stained and exa-
mined. Harvesting was delayed because majority of the parasites 
had not matured into schizonts. Cultures were further incubated for 
another 2 - 6 h until control wells revealed mature schizonts. Har-
vesting was then carried out. 
 
 
Harvesting and preparation of post-culture blood slides 
 
After incubation, the contents of the test wells were harvested by 
the removal of the supernatants with Pasteur pipettes. The red 
blood cells deposited on the flat bottom of each well were mixed 
and transferred carefully to a clean microscope slide, to form a 
series of thick films. The slides were air-dried for four days and then 
stained for 20 min with giemsa stain (10%v/v in water, pH 7.2). 
 
 
Analysis of the post-culture blood slides 
 
WHO standard counting procedure for quinine-chloroquine post 
culture thick films (WHO, 1990) was employed. In each thick film, 
the number of schizonts was expressed as parasites with 3 or more 
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Figure 1. Infra-red spectrum of quinine-zinc complex. 
 
 
nuclei per 200 asexual parasites, that is, total number of schizonts 
and trophozoites per 200 ring forms after incubation. The count was 
then expressed as a percentage of the control. 
Schizont inhibition and maturation were assessed in each well 
and the data obtained from the wells were processed to determine 
comparative sensitivity or resistance of P. falciparum to the drugs. 
 
 
Statistical analysis 
 
Students T- test (paired two-sample for means) was used for ana-
lysis of data for statistical significance (p < 0.05). 
 
 
RESULTS 
 
Identity and purity assessment test 
 
Quinine sulphate was extracted from Quinine sulphate 
tablets with percentage yield of 98.33%. The extracted 
QS and reference QS changed color at 190°C and mel-
ted with decomposition at 210°C. Single spot was 
observed for the extracted QS and reference QS on the 
chromatoplate with the same average retention factor (Rf) 
of 0.87 in methanol and ammonia and 0.26 in chloroform 
and methanol. Percentage yield of QZ obtained from 
complexing was 23.57% (1.6061 g). The melting point of 
the complex was 111°C, melting point of Quinine sul-
phate was 209°C, while the mixture of QS and QZ had a 
melting point of 162°C. Thin layer chromatography analy-
sis of QS and QZ gave single spot for each of QS and 
QZ, and Rf values 0.45 and 0.20 for QS and QZ respec- 
tively. 
The major IR peaks for QS in nujol were 730, 
1077,1156, 1235, 1381, 1457 , 1624 , 2962 while the IR 
peaks for the synthesized QZ in nujol were 730 , 901, 
1168,1387, 1466, 2858, 3733.8 as shown in Figures 1 
and 2. The uv spectra of both QS and QZ showed two 
maxima 203 and 246 nm as represented in Figure 3. 
There was therefore no difference in the maxima read-
ings of the uv spectra of the two substances. 
 
 
Schizont inhibition 
 
From the graph of percentage schizont inhibition versus 
drug concentration Figure 5 as obtained from data from 
Figure 4, the minimum inhibitory concentration (MIC) of 
QS was 2560 pmol/200 µl while that of QZ was 640 
pmol/200 µl, indicating that the amount of QZ required for 
effective schizonticidal action was three times less than 
that of QS. Drug concentration corresponding to 50% 
schizont inhibition (IC50) for QZ and QS are 3.98 and 
14.13 pmol/200 µl of drugs respectively. Schizont inhibi-
tion of QZ was significant over schizont inhibition of QS 
(p < 0.05). 
 
 
DISCUSSION 
 
The difference in the melting point of the complex (111oC) 
and that of the mixture of QS and QZ (162oC) indicated 
that the substances mixed were different, and supported 
the claim that QZ was synthesized. Comparative TLC 
analysis of QS and QZ showed that  Rf  for  QS  was  0.45 
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Figure 2. Infra-red spectrum of quinine sulphate. 
 
 
 
 
 
Figure 3. UV spectra of quinine sulphate and quinine-zinc 
complex. 
 
 
 
while that of QZ was 0.20.The melting point of the 
mixture of  QS  and  QZ  was  162oC.  This  melting  point 
 
 
Figure 4. Schizont count per 200 parasite test well following 
treatment with of quinine sulphate and quinine-zinc complex. 
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Figure 5. Percentage schizont inhibition by of quinine sulphate 
and quinine-zinc complex. 
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value, that is, 162oC is between the melting points of QZ 
(209oC) and QS (111oC). This melting point value 
obtained for the mixture of QS and QZ supported the idea 
that the substances mixed could have been QZ and QS. 
The IR peaks for QS in nujol as shown in Figure 2 were 
730 (aryl C-H  deformation), 1077 (methoxy C-O stretch-
ing), 1156 (alcoholic  O-H  deformation), 1235 (methoxy 
C-O stretching), 1381 (aryl C-N stretching), 1457 (alkyl C-
H deformation), 1624 (alkenes C=C stretching), 2962 
(alkyl C-H stretching) while the IR peaks for QZ in nujol 
as presented in Figure 1 were 730 (aryl C-H deforma-
tion), 901 (alkene C-H deformation), 1168 (alcoholic O-H 
deformation), 1387 (aryl C-N stretching), 1466 (alkyl O-H 
deformation), 2858 (aryl C-H stretching), 3733.8 (alcohol-
lic O-H stretching). The expressions in parenthesis 
describe the functional groups responsible for the IR 
peaks. An examination of the IR spectra of QS and QZ 
revealed a definite shift in the absorption of the alcoholic 
O-H group and an introduction of a new band for the 
complex at 3734 correlating with O-H stretching group. 
This shift occurred in the direction of longer wavelength 
for the group indicating that the O-H group of Quinine 
might be involved in the complexation with Zinc. Donation 
of electrons to metals by the ligand has been reported to 
produce lower excitation state, hence shifts to longer 
wavenumber (Mulliken, 1952). The ultraviolet spectra of 
QS and QZ complex in 0.1 M HCl showed two maximum 
absorptions at 230nm and 246nm indicating that there 
was no difference in the UV absorbance of QS and QZ. 
This is because Quinine has no chromophore for absorp-
tion in the UV region. Assessment of the zinc content of 
QZ prepared was done through Atomic absorption spectr-
oscopy. The zinc content obtained was used to calculate 
the mole ratio of complexation. The mole ratio was 
calculated to be 2:1 (Quinine:Zinc) supporting the report 
of Singla and Wadhwa (1994). From the graph of per-
centage schizont inhibition versus drug concentration, the 
minimum inhibitory concentration (MIC) of QS was 2560 
pmol/200 µl while that of QZ was 640 pmol/µl, indicating 
that the amount of QZ required for effective schizonticidal 
action was three times less than that of QS. Drug con-
centration corresponding to 50% schizont inhibition (IC50) 
for QZ and QS were 3.98 and 14.13 pmol/200 µl respec-
tively. Using students T-test (paired sample for means), 
statistical analysis of the data obtained showed that the 
difference in schizonticidal activities of QZ and QS were 
significant at 95% confidence limit (p< 0.05).  
 
 
Conclusion 
 
Quinine- Zinc complex (QZ) was synthesized in this 
experiment and its identity confirmed with UV, TLC, AAS 
and IR analysis. From in vitro micro test determination, 
complex was confirmed to have 3 times antimalarial po-
tency over Quinine sulphate. However, before Quinine 
Zinc complex can be recommended as a better alterna-
tive to Quinine and its various salts forms, its acute toxi-
city levels in vivo must be tested and established. Further  
 
 
 
 
research is also required to establish its therapeutic 
advantage with the use of well characterized susceptible 
and resistant strains of malaria parasite. 
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